About this Research Topic
Frontiers in Pharmacology is delighted to present the ‘Reviews in’ series of article collections.
"Reviews in Pharmacology of Anti-Cancer Drugs: 2023" will publish high-quality scholarly review papers on key topics in Pharmacology of Anti-Cancer Drugs. It aims to highlight recent advances in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the Pharmacology of Anti-Cancer Drugs community that will translate to best practice applications in clinical, public health and policy settings.
The Pharmacology of Anti-Cancer Drugs is a dynamic field, in which crucial advancements in targeted drug delivery systems, drug resistance mechanisms, and personalized treatment approaches, among others, are contributing to the development and optimization of effective therapies, playing a pivotal role in combating treatment failures, enhance drug effectiveness, and minimizing side effects. Collectively, the Pharmacology of Anti-Cancer Drug research community is driving the advancement of effective therapies, improving patient outcomes and promoting progress in the fight against cancer.
The "Reviews in Pharmacology of Anti-Cancer Drugs: 2023" collection welcomes full-length, mini or systematic review papers including, but not limited to, the following topics:
• Novel biocompatible drug delivery systems for targeted anti-cancer therapies, such as micro/nanoparticles, liposomes, hydrogels and polymer-based carriers.
• Pharmacological strategies to overcome tumor drug resistance, including combination therapies, drug repositioning, and the development of new drugs that target specific resistance pathways. Additionally, studies on molecular biomarkers predictive of anticancer drug response/resistance are welcome.
• Personalized medicine approaches in anti-cancer drug therapy exploring how genetic variations and individual patient characteristics can influence drug response and toxicity. It also discusses the potential of utilizing biomarkers and genotyping to guide treatment decisions and improve patient outcomes.
"Reviews in Pharmacology of Anti-Cancer Drugs: 2023" will publish high-quality scholarly review papers on key topics in Pharmacology of Anti-Cancer Drugs. It aims to highlight recent advances in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the Pharmacology of Anti-Cancer Drugs community that will translate to best practice applications in clinical, public health and policy settings.
The Pharmacology of Anti-Cancer Drugs is a dynamic field, in which crucial advancements in targeted drug delivery systems, drug resistance mechanisms, and personalized treatment approaches, among others, are contributing to the development and optimization of effective therapies, playing a pivotal role in combating treatment failures, enhance drug effectiveness, and minimizing side effects. Collectively, the Pharmacology of Anti-Cancer Drug research community is driving the advancement of effective therapies, improving patient outcomes and promoting progress in the fight against cancer.
The "Reviews in Pharmacology of Anti-Cancer Drugs: 2023" collection welcomes full-length, mini or systematic review papers including, but not limited to, the following topics:
• Novel biocompatible drug delivery systems for targeted anti-cancer therapies, such as micro/nanoparticles, liposomes, hydrogels and polymer-based carriers.
• Pharmacological strategies to overcome tumor drug resistance, including combination therapies, drug repositioning, and the development of new drugs that target specific resistance pathways. Additionally, studies on molecular biomarkers predictive of anticancer drug response/resistance are welcome.
• Personalized medicine approaches in anti-cancer drug therapy exploring how genetic variations and individual patient characteristics can influence drug response and toxicity. It also discusses the potential of utilizing biomarkers and genotyping to guide treatment decisions and improve patient outcomes.
Keywords: #CollectionSeries, #drug delivery, #biocompatible, #drug resistance, #personalized, #reviews
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
